“The current problem has exposed some structural weaknesses while in the EU’s medicines offer chain along with a substantial dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides mentioned. She recommended that supply chain challenges be tackled in an EU pharmaceutical technique predicted to be released by the end